Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Dristhi Ragoonanan(The University of Texas MD Anderson Cancer Center), Kris M. Mahadeo(The University of Texas MD Anderson Cancer Center), Keri Schadler(The University of Texas MD Anderson Cancer Center), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center), Leslie Lehmann(Harvard University), Natalie Dailey Garnes(National Institutes of Health), Priti Tewari(The University of Texas MD Anderson Cancer Center), Sangeeta Hingorani(University of Washington), Matteo Di Nardo(Bambino Gesù Children's Hospital), Ali Ahmad(The University of Texas MD Anderson Cancer Center), Jonathan Gill(Albert Einstein College of Medicine), Sajad Khazal(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Shulin Li(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(The University of Texas MD Anderson Cancer Center), Alison Gulbis(The University of Texas MD Anderson Cancer Center), Rita D. Swinford(The University of Texas Health Science Center at Houston), Maria E. Mireles(The University of Texas MD Anderson Cancer Center), Sung Won Choi(University of Michigan), Basirat Shoberu(Albert Einstein College of Medicine), David McCall(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(Cellular Therapeutics (United Kingdom)), Hisham Abdel‐Azim(University of Southern California), Selim Corbacioglu(Universität Ulm), Jeffery J. Auletta(NHS Blood and Transplant), Courtney M. Rowan(Children's Hospital of Wisconsin), Francesco Paolo Tambaro(The University of Texas MD Anderson Cancer Center), Julie C. Fitzgerald(Children's Hospital of Philadelphia), William G. Wierda(The University of Texas MD Anderson Cancer Center), Neena Kapoor(University of Southern California), Cristina Gutiérrez(The University of Texas MD Anderson Cancer Center), Marie E. Steiner, Paul L. Martin(Duke University), Fiorela N. Hernandez Tejada(The University of Texas MD Anderson Cancer Center), Joseph Angelo(Baylor College of Medicine), Christine Duncan(Dana-Farber Cancer Institute), Jennifer McArthur(St. Jude Children's Research Hospital), Linda Chi(The University of Texas MD Anderson Cancer Center), Rajinder Bajwa(Nationwide Children's Hospital), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Jeffrey D. Miller(The University of Texas MD Anderson Cancer Center)
Cited by 58
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782